Jingjing Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jingjing Zhao has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Wen Jiang
Department of Neurology, Xijing Hospital, Fourth Military Medical University, China
5 shared publications - Changgeng Song
Department of Neurology, Xijing Hospital Fourth Military Medical University Xi'an China
2 shared publications - Yaoyao Zhang
Department of Neurology, Xijing Hospital, Fourth Military Medical University, Xi'an, China
2 shared publications Bei Zhang
Department of Neurology, The First Affiliated Hospital of Xi’an Medical University, Xi’an, China
1 shared publication- Bin Wang
10 Department of Neurology, Jingyang County Hospital, Xianyang, China
1 shared publication Changgeng Song
Department of Neurology, Xijing Hospital, Fourth Military Medical University, Xi’an, China
1 shared publication
Latest Publications
- Open Access
- 9 October 2026
- Published by Springer Nature in Trials
- Vol. 27 (1) , 601
Advantage of cerebellar intermittent theta-burst stimulation in Alzheimer's disease (ACT-AD): study protocol for a multicenter, randomized, double-blind, sham-controlled trial
Introduction: The cerebellum plays a crucial role in cognitive processing and thus presents a promising therapeutic target for Alzheimer’s disease (AD). This trial aims to evaluate the efficacy and safety of long-term, neuronavigated cerebellar intermittent theta burst stimulation (iTBS) in patients with AD. Methods and analysis: The ACT-AD trial is a multicenter, randomized, double-blind, sham-controlled study involving 100 participants with mild-to-moderate AD across 4 centers in China. Participants will be randomized to receive either cerebellar iTBS or sham stimulation for 4 weeks (daily sessions), followed by 8 weeks of weekly maintenance sessions. The primary outcome is the change in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score from baseline to week 12. Secondary outcomes include additional clinical scales. Exploratory outcomes include electroencephalogram (EEG), blood biomarkers and magnetic resonance imaging (MRI). Statistical analysis will follow intention-to-treat principles using mixed models for repeated measures (MMRM). Discussion: The ACT-AD trial will assess the efficacy and safety of long-term, neuronavigated cerebellar iTBS in treating patients with mild-to-moderate AD. Trial registration: ClinicalTrials.gov, NCT06669182. Registered on 31 October 2024.
- 9 October 2026
- Published by Springer Nature in Trials
- Vol. 27 (1) , 601
Open AccessAdvantage of cerebellar intermittent theta-burst stimulation in Alzheimer's disease (ACT-AD): study protocol for a multicenter, randomized, double-blind, sham-controlled trial
Introduction: The cerebellum plays a crucial role in cognitive processing and thus presents a promising therapeutic target for Alzheimer’s disease (AD). This trial aims to evaluate the efficacy and safety of long-term, neuronavigated cerebellar intermittent theta burst stimulation (iTBS) in patients with AD. Methods and analysis: The ACT-AD trial is a multicenter, randomized, double-blind, sham-controlled study involving 100 participants with mild-to-moderate AD across 4 centers in China. Participants will be randomized to receive either cerebellar iTBS or sham stimulation for 4 weeks (daily sessions), followed by 8 weeks of weekly maintenance sessions. The primary outcome is the change in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score from baseline to week 12. Secondary outcomes include additional clinical scales. Exploratory outcomes include electroencephalogram (EEG), blood biomarkers and magnetic resonance imaging (MRI). Statistical analysis will follow intention-to-treat principles using mixed models for repeated measures (MMRM). Discussion: The ACT-AD trial will assess the efficacy and safety of long-term, neuronavigated cerebellar iTBS in treating patients with mild-to-moderate AD. Trial registration: ClinicalTrials.gov, NCT06669182. Registered on 31 October 2024.
- 28 March 2026
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 21 (1) , 16
Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis (MEET): A Proof of Concept Study
- 28 March 2026
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 21 (1) , 16
Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis (MEET): A Proof of Concept Study
- Open Access
Effects of minocycline on patients with acute anterior circulation ischaemic stroke undergoing intravenous thrombectomy (MIST-A): the study protocol for a multicentre, prospective, randomised, open-label, blinded-endpoint trial
Introduction Despite the implementation of mechanical thrombectomy, acute ischaemic stroke with large vessel occlusion (AIS-LVO) remains a significant health concern, characterised by substantial morbidity and mortality. Our trial aims to evaluate the efficacy and safety of minocycline in reducing infarct volume and improving functional outcomes in patients undergoing mechanical thrombectomy for anterior circulation AIS-LVO. Methods and analysis The MIST-A trial is a prospective, randomised, open-label, blinded-endpoint trial to be conducted across 12 medical centres. The study will enrol 180 adult patients who have experienced an anterior circulation AIS-LVO and have undergone mechanical thrombectomy. These patients will be randomly divided into two groups: one receiving minocycline in addition to standard care and the other receiving only standard care. The primary efficacy outcome is the change in infarct volume as measured by MRI, from baseline to day 5. The secondary efficacy outcomes include the incidence of intracerebral haemorrhage occurring within 24 hours and the clinical scores between the baseline and follow-up assessments. The primary outcome will be assessed using a mixed-effects model to determine the association between treatment and outcomes. Ethics and dissemination The study is approved by the Ethics Committee of Xijing Hospital (XJLL-KY20222186) and is registered at ClinicalTrials.gov (NCT05487417). This trial is estimated to end in the first quarter of 2025 and study findings are expected to be published in scientific journals that undergo peer review and also to be showcased at scientific conferences. Trial registration number NCT05487417.
Open AccessEffects of minocycline on patients with acute anterior circulation ischaemic stroke undergoing intravenous thrombectomy (MIST-A): the study protocol for a multicentre, prospective, randomised, open-label, blinded-endpoint trial
Introduction Despite the implementation of mechanical thrombectomy, acute ischaemic stroke with large vessel occlusion (AIS-LVO) remains a significant health concern, characterised by substantial morbidity and mortality. Our trial aims to evaluate the efficacy and safety of minocycline in reducing infarct volume and improving functional outcomes in patients undergoing mechanical thrombectomy for anterior circulation AIS-LVO. Methods and analysis The MIST-A trial is a prospective, randomised, open-label, blinded-endpoint trial to be conducted across 12 medical centres. The study will enrol 180 adult patients who have experienced an anterior circulation AIS-LVO and have undergone mechanical thrombectomy. These patients will be randomly divided into two groups: one receiving minocycline in addition to standard care and the other receiving only standard care. The primary efficacy outcome is the change in infarct volume as measured by MRI, from baseline to day 5. The secondary efficacy outcomes include the incidence of intracerebral haemorrhage occurring within 24 hours and the clinical scores between the baseline and follow-up assessments. The primary outcome will be assessed using a mixed-effects model to determine the association between treatment and outcomes. Ethics and dissemination The study is approved by the Ethics Committee of Xijing Hospital (XJLL-KY20222186) and is registered at ClinicalTrials.gov (NCT05487417). This trial is estimated to end in the first quarter of 2025 and study findings are expected to be published in scientific journals that undergo peer review and also to be showcased at scientific conferences. Trial registration number NCT05487417.
- 9 September 2022
- Published by Elsevier in Epilepsy & Behavior
- Vol. 135, 108904
Effects of antiepileptic drugs polytherapy on pregnancy outcomes in women with epilepsy: An observation study in northwest China
- 9 September 2022
- Published by Elsevier in Epilepsy & Behavior
- Vol. 135, 108904
Effects of antiepileptic drugs polytherapy on pregnancy outcomes in women with epilepsy: An observation study in northwest China
- 1 July 2019
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 69, 70-75
Long-term seizure outcome in patients with status epilepticus due to acute encephalitis
- 1 July 2019
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 69, 70-75
Long-term seizure outcome in patients with status epilepticus due to acute encephalitis